Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Imugene ( (AU:IMU) ).
Imugene Limited has applied for quotation on the ASX of 35,445,999 new fully paid ordinary shares, with an issue date of 20 March 2026. The additional securities, issued as part of previously announced transactions, will expand the company’s quoted share capital and may influence liquidity and ownership structure for existing and prospective investors.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australian biotechnology company listed on the ASX under the code IMU. The company operates in the biopharmaceutical sector, focusing on the research and development of immuno-oncology therapies for cancer treatment, targeting both domestic and international healthcare markets.
Average Trading Volume: 1,497,604
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$56.27M
Learn more about IMU stock on TipRanks’ Stock Analysis page.